Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06085209

Cryospray Therapy for Benign Airway Stenosis

This is a clinical evaluation to assess the effectiveness of cryospray therapy used in addition to current standard of care endoscopic therapies in preventing short term recurrent airway stenosis with a multicentric outcome evaluation. The investigators hypothesize that the addition of SCT to standard endoscopic treatment of benign airway stenosis will result in decreased stenosis recurrence at 6 months as estimated by quantitative radiologic assessment of the stenotic volume.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

About this study

Spray cryo treatment of tracheal stenosis has the potential for long-lasting endoscopic management of BCAS and is used as part of routine clinical care by many physicians, but there is a relative paucity of peer-reviewed data, and no randomized controlled trial has been performed. Thus, the study could potentially show that the use of spray cryo therapy could allow patients to undergo fewer procedures to treat this condition, or lengthen the amount of time required in between these procedures, or play a role in the resolution of this condition.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Referral to interventional pulmonology or otorhinolaryngology or thoracic surgery for endoscopic management of suspected benign tracheal stenosis.
  • Significant tracheal stenosis defined by stenosis ≥ 50% of tracheal lumen assessed on chest CT or previous bronchoscopy
  • Able to provide informed consent.
  • Age > 18

Exclusion criteria

  • Inability to provide informed consent
  • Pregnancy
  • Known or suspected malignant central airway stenosis
  • Patient has already been enrolled in this study.
  • Study subject has any disease or condition that interferes with safe completion of the study including:
  • Hypoxemia with need for supplemental oxygen ≥ 2L/min by nasal canula
  • Pneumothorax in the previous 12 months
  • Severe COPD (defined as a FEV1/FVC < 70% and FEV1 <30% predicted) and/or severe persistent asthma.
  • Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the attending physicians.
  • Compromised tissue where significant ulceration or mucosal break is evident in the ablation area or adjacent organs.
  • Significantly reduced tissue strength caused by prior procedure or pre-existing condition (e.g. PEG tube)
  • Significantly reduced elasticity of the ablation area (e.g. Marfan's Syndrome)
  • Prior complications with SCT (Spray cryotherapy)
  • Contraindication to rigid bronchoscopy
  • Significant tracheomalacia or alterations in cartilage integrity on CT (Computed Tomography) that would require stent placement or surgical referral.
  • Greater than 1 BCAS intervention, excluding cricotracheal (tracheal surgery) resection, within 6 months before enrollment.
  • Anatomical flow resistance (gas evacuation) where any procedure or anatomy proximal to the ablation site has significantly reduced or restricted the flow area of the lumen creating restriction where gas created from liquid nitrogen cannot adequately vent.

Treatment and study plan

The truFreeze Spray Cryotherapy

Device

A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.

Ballon Dilation

Device

An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.

Radial Incision

Device

Carbon dioxide (CO2) laser or Monopolar electrocautery knife

Primary outcomes

  1. Degree of re-stenosis

    Time frame: 6 months

    The degree of re-stenosis at 6 months expressed as the percentage of airway lumen volume within the stenotic segment at 6 months compared to personal best patency volume on CT scan performed within five weeks of the study intervention.

Secondary outcomes

  1. Change in Peak Expiratory Flow (PEF)

    Time frame: Continous for 6 months

    Evidence supports the use of PEF as a simple, efficient, and accessible way of monitoring progression of tracheal stenosis. PEF has previously been captured in clinical encounters as component of the decision-making algorithm for surgical intervention in tracheal stenosis patients. Mobile Device Software 'App' can robustly capture longitudinal patient reported outcome measures. A previously developed mobile device software 'Airflo' for tracking patient-generated health data and has proven the ability to successfully implement this software.

  2. Clinical Chronic Obstructive Pulmonary Disease Questionnaire (CCQ)

    Time frame: 2 weeks before procedure, 2 weeks after the procedure, the 3 month study mark, the 6 months study mark,

    The CCQ has been used as a validated quality of life measure in laryngotracheal stenosis. The investigators will send surveys out to patients at set time intervals to assess symptom improvement pre- and post-intervention. The questions are divided into three areas or domains. Symptoms 1, 2, 5, 6; Functional state 7, 8, 9, 10; Mental state 3 and 4. All items are equally weighted by adding score of ten items and dividing by the number ten. The score varies between 0 (very good health status) to 6 (extremely poor health status).

  3. Incidence of complications between groups

    Time frame: Continous for 6 months

    Incidence of complications (hypoxemia, bleeding, pneumothorax rate, barotrauma).

Study contacts

Contact information is provided by the study sponsor or research team.

Ramsha Hamid

CONTACT

[email protected]

(804) 628-2176

Sponsors and collaborators

Lead sponsor

Virginia Commonwealth University

Other

Collaborators

  • US Endoscopy Group Inc.

Registry information

Official study title

Cryospray Therapy for Benign Airway Stenosis: a Pilot Study (Pilot-CRYOSTASIS)

Acronym: CRYOSTASIS

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Oct 16, 2023
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.